ERBB2 and gastric cancer: PD1 inhibitors such as sintilimab (ORIENT-16) (56, 57) and pembrolizumab (KEYNOTE-859) (58) combined with standard chemotherapy can enhance the survival prognosis in advanced HER2-negative GC cases.